234 related articles for article (PubMed ID: 34546979)
1. Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa.
Hua VJ; Kilgour JM; Cho HG; Li S; Sarin KY
JCI Insight; 2021 Nov; 6(21):. PubMed ID: 34546979
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update.
Johnston LA; Alhusayen R; Bourcier M; Delorme I; George R; O'Brien E; Wong SM; Poelman SM
J Cutan Med Surg; 2022; 26(2_suppl):2S-24S. PubMed ID: 36000460
[TBL] [Abstract][Full Text] [Related]
4. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Garg A; Malviya N; Strunk A; Wright S; Alavi A; Alhusayen R; Alikhan A; Daveluy SD; Delorme I; Goldfarb N; Gulliver W; Hamzavi I; Jaleel T; Kimball AB; Kirby JS; Kirchhof MG; Lester J; Lev-Tov H; Lowes MA; Micheletti R; Orenstein LA; Piguet V; Sayed C; Tan J; Naik HB
J Am Acad Dermatol; 2022 May; 86(5):1092-1101. PubMed ID: 33493574
[TBL] [Abstract][Full Text] [Related]
5. All-cause mortality among patients with hidradenitis suppurativa: A population-based cohort study in the United States.
Reddy S; Strunk A; Garg A
J Am Acad Dermatol; 2019 Oct; 81(4):937-942. PubMed ID: 31202872
[TBL] [Abstract][Full Text] [Related]
6. Disease Trajectories for Hidradenitis Suppurativa in the Danish Population.
Kjærsgaard Andersen R; Jørgensen IF; Reguant R; Jemec GBE; Brunak S
JAMA Dermatol; 2020 Jul; 156(7):780-786. PubMed ID: 32432647
[TBL] [Abstract][Full Text] [Related]
7. Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: A retrospective analysis.
Seivright JR; Collier E; Grogan T; Hogeling M; Shi VY; Hsiao JL
Pediatr Dermatol; 2021 Sep; 38(5):1132-1136. PubMed ID: 34463372
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric comorbidities in patients with hidradenitis suppurativa.
Misitzis A; Goldust M; Jafferany M; Lotti T
Dermatol Ther; 2020 Jul; 33(4):e13541. PubMed ID: 32385861
[TBL] [Abstract][Full Text] [Related]
9. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.
Shlyankevich J; Chen AJ; Kim GE; Kimball AB
J Am Acad Dermatol; 2014 Dec; 71(6):1144-50. PubMed ID: 25440440
[TBL] [Abstract][Full Text] [Related]
10. Which hidradenitis suppurativa comorbidities should I take into account?
Tzellos T; Zouboulis CC
Exp Dermatol; 2022 Sep; 31 Suppl 1():29-32. PubMed ID: 35737874
[TBL] [Abstract][Full Text] [Related]
11. Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa [corrected].
Patel ZS; Hoffman LK; Buse DC; Grinberg AS; Afifi L; Cohen SR; Lowes MA; Seng EK
Curr Pain Headache Rep; 2017 Nov; 21(12):49. PubMed ID: 29094219
[TBL] [Abstract][Full Text] [Related]
12. Health care utilization patterns and costs for patients with hidradenitis suppurativa.
Kirby JS; Miller JJ; Adams DR; Leslie D
JAMA Dermatol; 2014 Sep; 150(9):937-44. PubMed ID: 24908260
[TBL] [Abstract][Full Text] [Related]
13. Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern.
Pinter A; Sarlak M; Zeiner KN; Malisiewicz B; Kaufmann R; Romanelli M; Koenig A; Chiricozzi A
Dermatology; 2021; 237(5):759-768. PubMed ID: 33326954
[TBL] [Abstract][Full Text] [Related]
14. Hidradenitis suppurativa and sleep: a systematic review.
Yeroushalmi S; Ildardashty A; Elhage KG; Chung M; Bartholomew E; Hakimi M; Tahir P; Naik HB; Bhutani T; Liao W
Arch Dermatol Res; 2023 Jul; 315(5):1409-1415. PubMed ID: 36396891
[TBL] [Abstract][Full Text] [Related]
15. Hidradenitis suppurativa: Epidemiology and scope of the problem.
Jemec GB; Kimball AB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S4-7. PubMed ID: 26470614
[TBL] [Abstract][Full Text] [Related]
16. Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data.
Marvel J; Vlahiotis A; Sainski-Nguyen A; Willson T; Kimball A
BMJ Open; 2019 Sep; 9(9):e030579. PubMed ID: 31575575
[TBL] [Abstract][Full Text] [Related]
17. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa.
Egeberg A; Gislason GH; Hansen PR
JAMA Dermatol; 2016 Apr; 152(4):429-34. PubMed ID: 26885728
[TBL] [Abstract][Full Text] [Related]
18. Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study.
Brown ID; Adawi W; Saal R; Perkins-Holtsclaw K; Roberts A
Clin Exp Dermatol; 2023 Apr; 48(5):524-527. PubMed ID: 36702792
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: A nationwide population-based cohort study.
Lee JW; Heo YW; Lee JH; Lee S
J Dermatol; 2023 Jun; 50(6):778-786. PubMed ID: 36806098
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities of hidradenitis suppurativa.
Porter ML; Kimball AB
Semin Cutan Med Surg; 2017 Jun; 36(2):55-57. PubMed ID: 28538744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
